Viatris
Community score
moreViatris emerged in November 2020 from the merger of Mylan N.V. and the Upjohn division of Pfizer, with its global headquarters situated in Canonsburg, Pennsylvania, United States. The company's operations span across several business segments which include Generic Drugs, offering an extensive array of generic pharmaceuticals such as tablets, capsules, injectables, and inhalants. Another segment covers Complex Generics and Biosimilars, featuring advanced generic drugs, like complex injectables, and biosimilars which are akin to original biologic drugs. Additionally, Viatris is involved in the marketing and selling of Branded Drugs in select therapeutic areas as well as providing Over-the-Counter (OTC) Medications that range from prescriptions to products for everyday consumer use. Among its portfolio, Viatris houses well-known brands like Lipitor® (atorvastatin), Norvasc® (amlodipine), Lyrica® (pregabalin), Viagra® (sildenafil citrate), and EpiPen® (epinephrine). The company's global reach extends to numerous countries, having a considerable market presence in regions including the United States, Europe, the Middle East, Asia, and Australia. (Powered by AI)
GHGs trap the Sun's heat and cause a rise in temperature, sea level, extreme weather conditions, and climate change1. Industries must develop carbon-free systems to meet the Paris Agreement's goal of keeping the atmospheric temperature rise below ...
In order to ensure strong institutions and the well-being of society, governments spend a considerable amount of the state's budget on public goods and services, which are funded by taxes paid by individuals and corporations1. On average, the stat...
Around 2 billion (Bn) people worldwide lack access to essential medications1;p1. At least 10% of the household budget of over 800 million (Mn) people goes into healthcare expenditure, and 100 Mn people are pushed to extreme poverty due to unafford...
The pharmaceutical industry plays a significant role in disease eradication and improving longevity by investing in R&D for novel cures and treatment options to tackle a wide range of illnesses helping patients live longer, healthier lives1. Accor...